SK147197A3 - Substituted oximes, hydrazones and olefins as neurokinin antagonists - Google Patents

Substituted oximes, hydrazones and olefins as neurokinin antagonists Download PDF

Info

Publication number
SK147197A3
SK147197A3 SK1471-97A SK147197A SK147197A3 SK 147197 A3 SK147197 A3 SK 147197A3 SK 147197 A SK147197 A SK 147197A SK 147197 A3 SK147197 A3 SK 147197A3
Authority
SK
Slovakia
Prior art keywords
mmol
added
product
alkyl
formula
Prior art date
Application number
SK1471-97A
Other languages
English (en)
Slovak (sk)
Inventor
Gregory A Reichard
Robert G Aslanian
Cheryl L Alaimo
Michael P Kirkup
Andrew Lupo
Pietro Mangiaracina
Kevin D Mccormick
John J Piwinski
Bandarpalle Shankar
Neng-Yang Shih
James M Spitler
Pauline C Ting
Ashit Ganguly
Nicholas I Carruthers
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of SK147197A3 publication Critical patent/SK147197A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SK1471-97A 1995-05-02 1996-05-01 Substituted oximes, hydrazones and olefins as neurokinin antagonists SK147197A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43274095A 1995-05-02 1995-05-02
US46081995A 1995-06-01 1995-06-01
PCT/US1996/005659 WO1996034857A1 (en) 1995-05-02 1996-05-01 Substituted oximes, hydrazones and olefins as neurokinin antagonists

Publications (1)

Publication Number Publication Date
SK147197A3 true SK147197A3 (en) 1998-08-05

Family

ID=27029621

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1471-97A SK147197A3 (en) 1995-05-02 1996-05-01 Substituted oximes, hydrazones and olefins as neurokinin antagonists

Country Status (23)

Country Link
US (2) US5696267A (ko)
EP (1) EP0823896B1 (ko)
JP (1) JP3255421B2 (ko)
KR (1) KR100248921B1 (ko)
CN (1) CN1134414C (ko)
AT (1) ATE203014T1 (ko)
AU (1) AU706526B2 (ko)
BR (1) BR9608269A (ko)
CA (1) CA2218913C (ko)
CZ (1) CZ342497A3 (ko)
DE (1) DE69613833T2 (ko)
DK (1) DK0823896T3 (ko)
ES (1) ES2158314T3 (ko)
GR (1) GR3036676T3 (ko)
HK (1) HK1008221A1 (ko)
HU (1) HU222048B1 (ko)
MX (1) MX9708415A (ko)
NO (1) NO310189B1 (ko)
NZ (1) NZ307715A (ko)
PL (1) PL323088A1 (ko)
PT (1) PT823896E (ko)
SK (1) SK147197A3 (ko)
WO (1) WO1996034857A1 (ko)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688960A (en) * 1995-05-02 1997-11-18 Schering Corporation Substituted oximes, hydrazones and olefins useful as neurokinin antagonists
US5945428A (en) * 1996-11-01 1999-08-31 Schering Corporation Substituted oximes, hydrazones and olefins as neurokinin antagonists
WO1999021823A1 (en) * 1997-10-27 1999-05-06 Schering Corporation Optically active intermediates for the preparation of optically active substituted oximes, hydrazones and olefins useful as neurokinin antagonists
US6265614B1 (en) 1997-10-27 2001-07-24 Schering Corporation Optically active intermediates for the preparation of optically active substituted oximes, hydrazones and olefins useful as neurokinin antagonists
PE134599A1 (es) * 1997-11-21 2000-01-07 Schering Corp Oximas sustituidas como antagonistas en neuroquinina
ID29137A (id) * 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1
US6103735A (en) * 1998-10-09 2000-08-15 Schering Corporation Composition and method for treating allergic diseases
US6221880B1 (en) 1998-10-09 2001-04-24 Schering Corporation Composition and method for treating allergic diseases
US6063926A (en) * 1998-11-18 2000-05-16 Schering Corporation Substituted oximes as neurokinin antagonists
US6204265B1 (en) 1998-12-23 2001-03-20 Schering Corporation Substituted oximes and hydrazones as neurokinin antagonists
TW533210B (en) * 1998-12-23 2003-05-21 Schering Corp Substituted oximes and hydrazones as neurokinin antagonists
US6348504B1 (en) 1999-03-30 2002-02-19 Richard E. Olson Oxime ethers as IIb/IIa antagonists
SE9902987D0 (sv) * 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
GB0011838D0 (en) * 2000-05-17 2000-07-05 Astrazeneca Ab Chemical compounds
ATE367811T1 (de) * 2000-06-12 2007-08-15 Univ Rochester Methode zur behandlung von hitzewallungen, durch verwendung eines tachikinin-rezeptor antagonisten
GB0104050D0 (en) * 2001-02-19 2001-04-04 Astrazeneca Ab Chemical compounds
GB0107228D0 (en) * 2001-03-22 2001-05-16 Astrazeneca Ab Chemical compounds
GB0108046D0 (en) * 2001-03-30 2001-05-23 Astrazeneca Ab Chemical compounds
AU2002259147A1 (en) 2001-05-08 2002-11-18 Schering Corporation Use of neurokinin receptor antagonists to treat androgen-dependent diseases
DK1404667T3 (da) 2001-07-02 2006-07-10 Astrazeneca Ab Piperidinderivater, der er anvendelige som modulatorer af chemokinreceptoraktivitet
UA75425C2 (en) 2001-07-09 2006-04-17 Piperazine oxime derivatives with antagonistic activity to nk-1 receptor, use thereof, a pharmaceutical composition based thereon, a method for producing and a method for producing intermediary compounds
GB0120461D0 (en) 2001-08-22 2001-10-17 Astrazeneca Ab Novel compounds
BR0212378A (pt) 2001-09-06 2004-10-19 Schering Corp Inibidores de 17beta-hidroxiesteróide desidrogenase tipo 3 para o tratamento de doenças dependentes de androgênio
GB0122503D0 (en) 2001-09-18 2001-11-07 Astrazeneca Ab Chemical compounds
CA2463626C (en) * 2001-10-17 2011-05-24 Schering Corporation Piperidine- and piperazineacetamines as 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
SE0103818D0 (sv) * 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
NZ535425A (en) 2002-03-13 2008-05-30 Biogen Idec Inc Anti-alphavbeta6 antibodies
SE0200844D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0200843D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
ATE522502T1 (de) 2002-11-25 2011-09-15 Mochida Pharm Co Ltd Therapeutisches mittel gegen atemwegserkrankungen,das ein 4-hydroxypiperidinderivat als wirkstoff enthält
SE0300957D0 (sv) 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
SE0301369D0 (sv) * 2003-05-09 2003-05-09 Astrazeneca Ab Chemical compounds
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
US20070020330A1 (en) 2004-11-24 2007-01-25 Medpointe Healthcare Inc. Compositions comprising azelastine and methods of use thereof
KR20070104884A (ko) 2004-11-24 2007-10-29 메드포인트 헬쓰케어 인크. 아젤라스틴을 포함하는 조성물 및 이의 사용 방법
US8758816B2 (en) 2004-11-24 2014-06-24 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
CN104072614B (zh) 2005-07-08 2017-04-26 生物基因Ma公司 抗-αvβ6 抗体及其用途
EP2402316A1 (en) 2005-07-21 2012-01-04 AstraZeneca AB (Publ) Piperidine derivatives
KR100997549B1 (ko) * 2005-08-15 2010-11-30 에프. 호프만-라 로슈 아게 Ｐ2ｘ3 길항제로서의 피페리딘 및 피페라진 유도체
US20100016289A1 (en) * 2005-11-01 2010-01-21 Kevin Sprott Compounds Useful as Antagonists of CCR2
US8067415B2 (en) * 2005-11-01 2011-11-29 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of CCR2
WO2007053498A1 (en) * 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of ccr2
US20070116818A1 (en) * 2005-11-22 2007-05-24 Toyo Seikan Kaisha, Ltd. Extract containing beta-cryptoxanthin component from persimmon fruit
US8247442B2 (en) 2006-03-29 2012-08-21 Purdue Pharma L.P. Benzenesulfonamide compounds and their use
US8791264B2 (en) 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
TW200812963A (en) 2006-04-13 2008-03-16 Euro Celtique Sa Benzenesulfonamide compounds and the use thereof
AU2007272995B2 (en) 2006-07-10 2013-02-07 Biogen Idec Ma Inc. Compositions and methods for inhibiting growth of smad4-deficient cancers
TW200831497A (en) * 2006-10-12 2008-08-01 Epix Delaware Inc Carboxamide compounds and their use
WO2008090117A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1
US8399486B2 (en) * 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
ES2382415T3 (es) * 2007-09-14 2012-06-08 F. Hoffmann-La Roche Ag Derivados de piperidina como antagonistas de receptores de NK3
WO2009040659A2 (en) 2007-09-28 2009-04-02 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
US8569282B2 (en) 2007-12-11 2013-10-29 Cytopathfinder, Inc. Carboxamide compounds and their use
KR20150046259A (ko) 2012-08-23 2015-04-29 앨리오스 바이오파마 인크. 파라믹소바이러스 바이러스성 감염의 치료용 화합물
WO2014144466A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
WO2014143739A2 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
US10987322B2 (en) 2014-06-06 2021-04-27 Flexus Biosciences, Inc. Immunoregulatory agents
WO2016071792A1 (en) * 2014-11-03 2016-05-12 Laboratorio Chimico Internazionale S.P.A. Method for the preparation of 1-(2-halogen-ethyl)-4 piperidine-carboxylic acid ethyl esters
EP3061501A1 (en) 2015-02-27 2016-08-31 Rottapharm Ltd. Composition for the treatment of acne
EP3117825A1 (en) 2015-07-16 2017-01-18 Rottapharm S.p.A. Oral formulation comprising berberine and morus alba extract
CN105481623B (zh) * 2015-12-01 2017-10-27 上海澄厚菲贸易有限公司 一种羟乙基苯胺酯化物(iii)的合成工艺
JP7256509B2 (ja) * 2016-08-22 2023-04-12 エルゴン ファーマシューティカルズ エルエルシー Ｂｃａｔ１阻害剤を使用する組成物及び治療方法
WO2019018185A1 (en) 2017-07-15 2019-01-24 Arisan Therapeutics Inc. ENANTIOMERICALLY PURE ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTIONS
CN113087689B (zh) * 2021-03-10 2023-09-29 中国人民解放军空军军医大学 5-氨基-γ-内酯衍生物的简便合成方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2473518A1 (fr) * 1980-01-16 1981-07-17 Unicler Derives du phenyl-1 morpholino-4 butene-1 ol-3, leur preparation et leur application en therapeutique
IL99320A (en) * 1990-09-05 1995-07-31 Sanofi Sa Arylalkylamines, their preparation and pharmaceutical preparations containing them
EP0593557B1 (en) * 1991-07-05 1996-01-31 MERCK SHARP & DOHME LTD. Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
WO1993001169A2 (en) * 1991-07-05 1993-01-21 Merck Sharp & Dohme Limited Aromatic compounds, pharmaceutical compositions containing them and their use in therapy
DK0641328T3 (da) * 1992-05-18 2002-05-21 Pfizer Broforbundne, azabicykliske derivater som substans P-antagonister
GB9321557D0 (en) * 1992-11-03 1993-12-08 Zeneca Ltd Carboxamide derivatives
FR2700472B1 (fr) * 1993-01-19 1995-02-17 Rhone Poulenc Rorer Sa Association synergisante ayant un effet antagoniste des récepteurs NK1 et NK2.
AU6226494A (en) * 1993-03-04 1994-09-26 Pfizer Inc. Spiroazacyclic derivatives as substance p antagonists
GB9310713D0 (en) * 1993-05-24 1993-07-07 Zeneca Ltd Aryl substituted heterocycles
EP0702681A1 (en) * 1993-06-07 1996-03-27 Merck & Co. Inc. Spiro-substituted azacycles as neurokinin antagonists
GB9317104D0 (en) * 1993-08-17 1993-09-29 Zeneca Ltd Therapeutic heterocycles
GB9322643D0 (en) * 1993-11-03 1993-12-22 Zeneca Ltd Lactam derivatives
FR2717802B1 (fr) * 1994-03-25 1996-06-21 Sanofi Sa Nouveaux composés aromatiques, procédé pour leur préparation et compositions pharmaceutiques en contenant.
GB9408872D0 (en) * 1994-05-03 1994-06-22 Zeneca Ltd Heterocyclic compounds
CA2154116A1 (en) * 1994-07-22 1996-01-23 Philip Arthur Hipskind 1-aryl-2-acetamidopentanone derivatives for use as tachykinin receptor antagonists

Also Published As

Publication number Publication date
JPH10506923A (ja) 1998-07-07
AU5714096A (en) 1996-11-21
US5840725A (en) 1998-11-24
ES2158314T3 (es) 2001-09-01
CZ342497A3 (cs) 1998-07-15
BR9608269A (pt) 1999-02-17
HUP9800840A3 (en) 1998-09-28
EP0823896B1 (en) 2001-07-11
PL323088A1 (en) 1998-03-02
AU706526B2 (en) 1999-06-17
EP0823896A1 (en) 1998-02-18
NO975029D0 (no) 1997-10-31
CA2218913C (en) 2003-03-04
PT823896E (pt) 2001-11-30
DE69613833T2 (de) 2002-04-04
HK1008221A1 (en) 1999-05-07
CN1189821A (zh) 1998-08-05
US5696267A (en) 1997-12-09
ATE203014T1 (de) 2001-07-15
CN1134414C (zh) 2004-01-14
KR19990008231A (ko) 1999-01-25
NO310189B1 (no) 2001-06-05
HU222048B1 (hu) 2003-04-28
JP3255421B2 (ja) 2002-02-12
WO1996034857A1 (en) 1996-11-07
CA2218913A1 (en) 1996-11-07
NO975029L (no) 1997-12-30
DE69613833D1 (de) 2001-08-16
MX9708415A (es) 1998-02-28
GR3036676T3 (en) 2001-12-31
KR100248921B1 (ko) 2000-04-01
DK0823896T3 (da) 2001-09-24
NZ307715A (en) 2000-01-28
HUP9800840A2 (hu) 1998-08-28

Similar Documents

Publication Publication Date Title
SK147197A3 (en) Substituted oximes, hydrazones and olefins as neurokinin antagonists
JP3063164B2 (ja) 含フッ素１，４−ジ置換ピペリジン誘導体
EP0532456B1 (de) 1-Acylpiperidinverbindungen und ihre Verwendung als Substanz P Artagonisten
KR100229117B1 (ko) 피페리딘 유도체
KR100413150B1 (ko) 5-에이치티4 수용체 길항제로서의 디하이드로벤조디옥신 카복스아미드 및 케톤 유도체
US8765750B2 (en) Piperazine compound having a PGDS inhibitory effect
JP2007320966A (ja) 治療用複素環式化合物
JPH10513191A (ja) タキキニン受容体アンタゴニストとしての５−（４−置換−ピペリジニル−１）−３−アリール−ペンタン酸誘導体
JP5140226B2 (ja) アミノアルコキシベンゾイル−ベンゾフランまたはベンゾチオフェン誘導体、その製造方法およびそれを含む組成物
KR100416674B1 (ko) 크로몬유도체
JP2014526547A (ja) バニロイド受容体リガンドとしての置換メタンスルホンアミド誘導体
ES2396557T3 (es) Derivado de benciloxipropilamina
CA2268866C (en) Substituted arylalkylamines as neurokinin antagonists
JP2001524466A (ja) ニューロキニンアンタゴニストとしての置換されたオキシム
DE69626123T2 (de) Substituierte benzokondensierte heterocyclen als neurokinin antagonisten
JP3282618B2 (ja) 含フッ素１，４−ジ置換ピペリジン誘導体の新規製造中間体
JP3282617B2 (ja) 含フッ素１，４−ジ置換ピペリジン誘導体の新規製造中間体
MXPA99003894A (en) Substituted arylalkylamines as neurokinin antagonists